Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03611686
  4. Details
NCT03611686 Clinical Trial

Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies

Metastatic Prostate Adenocarcinoma Clinical Trial

— OPALE  

Official title:
Observatory of Patients With Metastatic ProstAte Adenocarcinoma That is Resistant to Castration and Multi-LinE Strategies

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT03611686
Other study ID # 2017/090/HP
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 17, 2018
Est. completion date April 2026

Study information
Verified date November 2019
Source University Hospital, Rouen
Contact Sophie GOUERANT, MD
Phone +3323288
Email sophie.gouerant@chu-rouen.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Evaluation the overall survival of patients with metastatic prostate adenocarcinoma resistant to castration

Recruitment information / eligibility
Status Recruiting
Enrollment 500
Est. completion date April 2026
Est. primary completion date April 2026
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient monitored for castration-resistant metastatic prostate

- Patients starting a first or second line treatment as part of castration resistance

- Patient not objecting to the study after reading the information letter

- Patient aged over 18 years

Exclusion Criteria:

- Patient monitored for non-metastatic prostate cancer

- Patient monitored for castration-nonresistant prostate cancer

- Patient not able to understand the information letter

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Local chemotherapy
Local chemotherapy will be administrated according to local recommendation

Locations
Country Name City State
France Rouen University Hospital Rouen

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of alive patient 3 years
Secondary Number of alive patient disease free 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04033432 - sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Not yet recruiting NCT06236139 - Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Phase 1/Phase 2
Recruiting NCT04734730 - Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer Phase 2
Recruiting NCT06039371 - Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study Phase 2
Withdrawn NCT04781374 - Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer Phase 2
Recruiting NCT05689021 - CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Phase 2
Recruiting NCT05796973 - Measuring Oncological Value of Exercise and Statin Phase 3
Recruiting NCT05054296 - Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring Phase 2
Active, not recruiting NCT03902951 - Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer Phase 2
Recruiting NCT05168618 - Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial Phase 2
Recruiting NCT05445609 - Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05479578 - Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer Phase 1
Recruiting NCT05113537 - Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer Phase 1/Phase 2
Active, not recruiting NCT04754425 - Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer Phase 2
Active, not recruiting NCT04190446 - Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized Treatment Phase 2
Recruiting NCT04471974 - ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer Phase 2
Completed NCT05573789 - Tumor Molecular Profiling in Patients With Prostate Cancer
Active, not recruiting NCT02099864 - Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy Phase 2
Suspended NCT03317392 - Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis Phase 1/Phase 2
Active, not recruiting NCT04455750 - A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy Phase 3